index	sentence
0	Activating @Gene$ mutations outwith 'hotspot' codons in sporadic @Disease$ - implications for personalised cancer medicine
1	Activating @Gene$ mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised @Disease$ medicine
2	Response to @Gene$-targeted therapies in @Disease$ patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status
3	Response to EGFR-targeted therapies in @Disease$ patients has been convincingly associated with @Gene$ (K-Ras) mutation status
4	Response to EGFR-targeted therapies in @Disease$ patients has been convincingly associated with Kirsten-Ras (@Gene$) mutation status
5	@Disease$ (n=106) were screened for additional @Gene$ mutations, phenotypes compared in transformation and Ras GTPase activating assays and gene and pathway changes induced by individual K-Ras mutants identified by microarray analysis
6	@Disease$ (n=106) were screened for additional K-Ras mutations, phenotypes compared in transformation and Ras GTPase activating assays and gene and pathway changes induced by individual @Gene$ mutants identified by microarray analysis
7	Four additional @Gene$ mutations (Leu19Phe (1 out of 106 @Disease$), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified
8	We additionally identified a new @Gene$ gene amplification event, present in approximately 2% of @Disease$.
9	The identification of mutations outwith previously described hotspot codons increases the @Gene$ mutation burden in @Disease$ by one-third
10	A genetic model for @Disease$ highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and @Gene$ and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
11	A genetic model for @Disease$ highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene @Gene$ (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
12	A genetic model for @Disease$ highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (@Gene$), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
13	A genetic model for colorectal cancer highlighted key genes, including the @Disease$ suppressor genes adenomatous polyposis coli (APC) and @Gene$ and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
14	A genetic model for colorectal cancer highlighted key genes, including the @Disease$ suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene @Gene$ (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
15	A genetic model for colorectal cancer highlighted key genes, including the @Disease$ suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (@Gene$), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
16	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes @Disease$ (APC) and @Gene$ and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
17	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes @Disease$ (APC) and p53 and the oncogene @Gene$ (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
18	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes @Disease$ (APC) and p53 and the oncogene Kirsten-Ras (@Gene$), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
19	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (@Disease$) and @Gene$ and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
20	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (@Disease$) and p53 and the oncogene @Gene$ (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
21	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (@Disease$) and p53 and the oncogene Kirsten-Ras (@Gene$), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)
22	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and @Gene$ and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the @Disease$ transition (Vogelstein et al, 1988)
23	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene @Gene$ (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the @Disease$ transition (Vogelstein et al, 1988)
24	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (@Gene$), the progressive acquisition of mutations in which was proposed to regulate the @Disease$ transition (Vogelstein et al, 1988)
25	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in @Gene$ mutation frequency in @Disease$, suggesting that K-Ras mutation status may be an important determinant of tumour progression
26	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in @Gene$ mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of @Disease$ progression
27	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in @Disease$, suggesting that @Gene$ mutation status may be an important determinant of tumour progression
28	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that @Gene$ mutation status may be an important determinant of @Disease$ progression
29	We additionally used comparative genomic hybridisation (CGH) analysis to identify common chromosomal aberrations in @Disease$, and highlighted an amplification of the region of chromosome 12p where the @Gene$ gene is localised (Leslie et al, 2003)
30	We and others have shown that @Gene$ mutations are associated with significantly reduced survival in @Disease$ patients (Andreyev et al, 2001; Conlin et al, 2005), although previous data is not entirely consistent (Etienne-Grimaldi et al, 2008; Winder et al, 2009)
31	@Gene$ mutation status has recently been convincingly associated with response to the new generation EGFR antagonists cetuximab (Erbitux) and panitumumab (Vectibix), where response is preferentially observed in wt @Disease$ (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009)
32	K-Ras mutation status has recently been convincingly associated with response to the new generation @Gene$ antagonists cetuximab (Erbitux) and panitumumab (Vectibix), where response is preferentially observed in wt @Disease$ (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009)
33	@Gene$ mutation testing is therefore increasingly recommended to facilitate selection of the most appropriate patients for treatment with EGFR antagonists (McNeill, 2008; @Disease$ and Tol, 2009).
34	K-Ras mutation testing is therefore increasingly recommended to facilitate selection of the most appropriate patients for treatment with @Gene$ antagonists (McNeill, 2008; @Disease$ and Tol, 2009).
35	Previous analyses of @Gene$ mutations in human @Disease$ have consistently focussed on single-point mutations in codons 12, 13 and 61, where mutation has been shown to result in reduced Ras GAP GTPase activity, locking the protein in the active Ras-GTP conformation (Ellis and Clark, 2000), although additional mutations at codons 19, 22 and 146 have been described in single colorectal tumour case reports (Orita et al, 1991; Miyakura et al, 2002; Akagi et al, 2007).
36	Previous analyses of @Gene$ mutations in human tumours have consistently focussed on single-point mutations in codons 12, 13 and 61, where mutation has been shown to result in reduced Ras GAP GTPase activity, locking the protein in the active Ras-GTP conformation (Ellis and Clark, 2000), although additional mutations at codons 19, 22 and 146 have been described in single @Disease$ case reports (Orita et al, 1991; Miyakura et al, 2002; Akagi et al, 2007).
37	@Gene$ mutations have also been identified in human @Disease$, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)
38	@Gene$ mutations have also been identified in human cancers, including @Disease$ and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)
39	@Gene$ mutations have also been identified in human cancers, including melanoma and thyroid, @Disease$, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)
40	@Gene$ mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in @Disease$ vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)
41	@Gene$ mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with @Disease$ in mismatch-repair activity (Wellbrock et al, 2004)
42	The most common @Gene$ mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant @Disease$ (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)
43	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of @Gene$ mutant @Disease$ (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)
44	Although @Gene$ and B-Raf mutations are found in the same @Disease$ types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of K-Ras signalling pathways
45	Although K-Ras and @Gene$ mutations are found in the same @Disease$ types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of K-Ras signalling pathways
46	Although K-Ras and B-Raf mutations are found in the same @Disease$ types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of @Gene$ signalling pathways
47	@Gene$ mutation status has also recently been associated with response to cetuximab and panitumumab where, like K-Ras, clinical response is limited to wt @Disease$ (Di Nicolantonio et al, 2008).
48	B-Raf mutation status has also recently been associated with response to cetuximab and panitumumab where, like @Gene$, clinical response is limited to wt @Disease$ (Di Nicolantonio et al, 2008).
49	As @Gene$ mutations in @Disease$ are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.
50	As @Gene$ mutations in colorectal tumours are clearly important biomarkers of @Disease$ progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.
51	As K-Ras mutations in @Disease$ are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation @Gene$ antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.
52	As K-Ras mutations in @Disease$ are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in @Gene$ mutation burden.
53	As K-Ras mutations in colorectal tumours are clearly important biomarkers of @Disease$ progression and patient survival and also influence response to new generation @Gene$ antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.
54	As K-Ras mutations in colorectal tumours are clearly important biomarkers of @Disease$ progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in @Gene$ mutation burden.
55	@Gene$ was amplified from genomic DNA extracted from normal and @Disease$ tissues (n=96 normal/tumour pairs) from our colorectal patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).
56	@Gene$ was amplified from genomic DNA extracted from normal and tumour tissues (n=96 normal/@Disease$ pairs) from our colorectal patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).
57	@Gene$ was amplified from genomic DNA extracted from normal and tumour tissues (n=96 normal/tumour pairs) from our @Disease$ patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).
58	Meanwhile, 1 mul chromosome 12p BAC @Gene$-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing @Disease$ tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue
59	Meanwhile, 1 mul chromosome 12p BAC @Gene$-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and @Disease$ tissue
60	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC @Gene$-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing @Disease$ tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue
61	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC @Gene$-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and @Disease$ tissue
62	We have previously described @Gene$ mutations at codons 12, 13 and 61 in a series of 106 unselected @Disease$ (Smith et al, 2002)
63	Mutations at codon 19 (G57T, Leu19Phe) and in @Gene$ (V600E) were found in single @Disease$ (Table 2).
64	To identify additional @Gene$ mutations, and to establish the relative frequencies of individual K-Ras mutations in human @Disease$, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant
65	To identify additional @Gene$ mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same @Disease$ series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant
66	To identify additional K-Ras mutations, and to establish the relative frequencies of individual @Gene$ mutations in human @Disease$, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant
67	To identify additional K-Ras mutations, and to establish the relative frequencies of individual @Gene$ mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same @Disease$ series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant
68	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human @Disease$, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in @Gene$ exon 3 and exon 4B, the most common exon 4 splice variant
69	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same @Disease$ series for mutations in @Gene$ exon 3 and exon 4B, the most common exon 4 splice variant
70	To determine the frequencies of the codon 117, 146 and 164 @Gene$ mutations and the codon 173 SNP, PCR-RFLP assays were designed to permit rapid screening of blood and @Disease$ DNA (Appendix A)
71	No @Disease$ with codon 19, 117, 146 or 146 mutations had additional @Gene$ mutations in codons 12, 13 or 61
72	To investigate whether altered @Gene$ activity could additionally result from gene amplification, a K-Ras gene copy number assay was designed and carried out as described in Materials and Methods and K-Ras copy number compared in normal and @Disease$ tissues
73	To investigate whether altered K-Ras activity could additionally result from gene amplification, a @Gene$ gene copy number assay was designed and carried out as described in Materials and Methods and K-Ras copy number compared in normal and @Disease$ tissues
74	To investigate whether altered K-Ras activity could additionally result from gene amplification, a K-Ras gene copy number assay was designed and carried out as described in Materials and Methods and @Gene$ copy number compared in normal and @Disease$ tissues
75	In total, 2 of the 96 @Disease$ pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt @Gene$) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene
76	In total, 2 of the 96 @Disease$ pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of @Gene$ and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene
77	In total, 2 of the 96 @Disease$ pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt @Gene$) with 27 copies of the K-Ras gene
78	In total, 2 of the 96 @Disease$ pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the @Gene$ gene
79	In total, 2 of the 96 tumour pairs analysed (2.1%) showed @Disease$-specific copy number increases (Figure 6), one (study code 1264, wt @Gene$) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene
80	In total, 2 of the 96 tumour pairs analysed (2.1%) showed @Disease$-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of @Gene$ and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene
81	In total, 2 of the 96 tumour pairs analysed (2.1%) showed @Disease$-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt @Gene$) with 27 copies of the K-Ras gene
82	In total, 2 of the 96 tumour pairs analysed (2.1%) showed @Disease$-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the @Gene$ gene
83	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt @Gene$) with 4 @Disease$ copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene
84	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 @Disease$ copies of @Gene$ and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene
85	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 @Disease$ copies of K-Ras and the other (study code 1233, wt @Gene$) with 27 copies of the K-Ras gene
86	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 @Disease$ copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the @Gene$ gene
87	Figure 7C illustrates a @Disease$ sample (study code 1271) in which the @Gene$ gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)
88	Figure 7C illustrates a @Disease$ sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with @Gene$ gene amplification (red fluorescence>green fluorescence)
89	Figure 7C illustrates a tumour sample (study code 1271) in which the @Gene$ gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a @Disease$ (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)
90	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a @Disease$ (study code 1264) with @Gene$ gene amplification (red fluorescence>green fluorescence)
91	Recent clinical data has shown a compelling association between @Gene$ and B-Raf mutation status and response to EGFR blockade by cetuximab and panitumumab in the treatment of metastatic @Disease$ (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)
92	Recent clinical data has shown a compelling association between K-Ras and @Gene$ mutation status and response to EGFR blockade by cetuximab and panitumumab in the treatment of metastatic @Disease$ (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)
93	Recent clinical data has shown a compelling association between K-Ras and B-Raf mutation status and response to @Gene$ blockade by cetuximab and panitumumab in the treatment of metastatic @Disease$ (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)
94	@Gene$ mutations in @Disease$ have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)
95	@Gene$ mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 @Disease$ estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)
96	K-Ras mutations in @Disease$ have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average @Gene$ mutation frequency of 34.8% (Andreyev et al, 2001)
97	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 @Disease$ estimates an average @Gene$ mutation frequency of 34.8% (Andreyev et al, 2001)
98	Although additional @Gene$ mutations have been reported outwith these 'hotspot' codons, to our knowledge, there has been no systematic analysis of K-Ras mutation frequency in human @Disease$
99	Although additional K-Ras mutations have been reported outwith these 'hotspot' codons, to our knowledge, there has been no systematic analysis of @Gene$ mutation frequency in human @Disease$
100	Our use of 'WAVE' denaturing HPLC (dHPLC) analysis (Kuklin et al, 1997) allowed us to carry out a rapid, systematic analysis of the entire @Gene$ coding sequence to identify @Disease$ with sequence changes, the nature which were subsequently confirmed by conventional dideoxy sequencing.
101	Our data clearly demonstrates that @Gene$ mutations in human @Disease$ are likely to be significantly underestimated if only hotspot codons are analysed
102	Current data from the COSMIC database, which summarises literature data and the ongoing Sanger @Disease$-genome project describes 29 @Gene$ colorectal tumour mutations outwith codons 12, 13 and 61, and more than 11 800 mutations at these hotspot codons (http://www.sanger.ac.uk/genetics/CGP/), but does not describe associated phenotypes
103	Current data from the COSMIC database, which summarises literature data and the ongoing Sanger cancer-genome project describes 29 @Gene$ @Disease$ mutations outwith codons 12, 13 and 61, and more than 11 800 mutations at these hotspot codons (http://www.sanger.ac.uk/genetics/CGP/), but does not describe associated phenotypes
104	@Gene$ codon 146 mutations have been described in a human @Disease$ cell line (Higashi et al, 1990), in mice with thymic lymphomas (Sloan et al, 1990) and in a single human colorectal tumour case report (Orita et al, 1991)
105	@Gene$ codon 146 mutations have been described in a human colorectal tumour cell line (Higashi et al, 1990), in mice with @Disease$ (Sloan et al, 1990) and in a single human colorectal tumour case report (Orita et al, 1991)
106	@Gene$ codon 146 mutations have been described in a human colorectal tumour cell line (Higashi et al, 1990), in mice with thymic lymphomas (Sloan et al, 1990) and in a single human @Disease$ case report (Orita et al, 1991)
107	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the @Gene$ 146 mutation in @Disease$ and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.
108	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the @Gene$ 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic @Disease$ with a K-Ras 146 mutation was resistant to cetuximab.
109	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in @Disease$ and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a @Gene$ 146 mutation was resistant to cetuximab.
110	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic @Disease$ with a @Gene$ 146 mutation was resistant to cetuximab.
111	There is only a single report of @Gene$ codon 19 mutations in human @Disease$ (Akagi et al, 2007), in which in vitro elevation of active Ras-GTP levels, anchorage-independent growth and increased tumourigenicity in nude mice was demonstrated
112	A codon 19 mutation has additionally been described in @Gene$ in a human @Disease$ (Pei et al, 1994)
113	There are two recent reports of codon 117 mutations - the first in @Gene$ in human @Disease$ (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)
114	There are two recent reports of codon 117 mutations - the first in @Gene$ in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the @Disease$ (Denayer et al, 2008)
115	There are two recent reports of codon 117 mutations - the first in K-Ras in human @Disease$ (Wojcik et al, 2008) and the second in @Gene$, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)
116	There are two recent reports of codon 117 mutations - the first in K-Ras in human @Disease$ (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-@Gene$ pathway and the mental retardation Costello syndrome (Denayer et al, 2008)
117	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in @Gene$, associated with activation of the RAS-MAPK pathway and the @Disease$ (Denayer et al, 2008)
118	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-@Gene$ pathway and the @Disease$ (Denayer et al, 2008)
119	There are no reports of @Gene$ 164 mutations, and mutations at this codon were not identified by Sanger @Disease$ genome project investigators.
120	Recent clinical data convincingly associates response to anti-@Gene$ therapies with K-Ras mutation status in patients with metastatic @Disease$ where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade
121	Recent clinical data convincingly associates response to anti-@Gene$ therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in @Disease$ (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade
122	Recent clinical data convincingly associates response to anti-EGFR therapies with @Gene$ mutation status in patients with metastatic @Disease$ where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade
123	Recent clinical data convincingly associates response to anti-EGFR therapies with @Gene$ mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in @Disease$ (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade
124	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic @Disease$ where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to @Gene$ blockade
125	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in @Disease$ (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to @Gene$ blockade
126	Our description of @Gene$ gene amplification in a subset of wt @Disease$ is of particular interest in this regard as increased K-Ras gene copy number may lead to a more active 'mutation'-like phenotype
127	Our description of K-Ras gene amplification in a subset of wt @Disease$ is of particular interest in this regard as increased @Gene$ gene copy number may lead to a more active 'mutation'-like phenotype
128	Consistent with our own data, @Gene$ expression has previously been shown to be increased in @Disease$ with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)
129	Consistent with our own data, @Gene$ expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of @Disease$ types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)
130	Consistent with our own data, DUSP4 expression has previously been shown to be increased in @Disease$ with @Gene$ mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)
131	Consistent with our own data, DUSP4 expression has previously been shown to be increased in @Disease$ with K-Ras mutations (Yip-Schneider et al, 2001) and @Gene$ expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)
132	Consistent with our own data, DUSP4 expression has previously been shown to be increased in @Disease$ with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or @Gene$ pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)
133	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with @Gene$ mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of @Disease$ types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)
134	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and @Gene$ expression increased in a variety of @Disease$ types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)
135	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of @Disease$ types with mutations in Ras or @Gene$ pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)
136	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by @Gene$ and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both @Disease$ progression and treatment response
137	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and @Gene$, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both @Disease$ progression and treatment response
138	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 @Gene$ mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both @Disease$ progression and treatment response
139	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual @Gene$ mutations may be important determinants of both @Disease$ progression and treatment response
140	For example, recent data suggests that @Disease$ can promote the acquisition of @Gene$ mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)
141	For example, recent data suggests that @Disease$ can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter @Gene$ in K-Ras mutant tumours (Yun et al, 2009)
142	For example, recent data suggests that @Disease$ can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in @Gene$ mutant tumours (Yun et al, 2009)
143	For example, recent data suggests that glucose deprivation can promote the acquisition of @Gene$ mutations in human @Disease$ and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)
144	For example, recent data suggests that glucose deprivation can promote the acquisition of @Gene$ mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant @Disease$ (Yun et al, 2009)
145	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human @Disease$ and reports upregulation of the glucose transporter @Gene$ in K-Ras mutant tumours (Yun et al, 2009)
146	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human @Disease$ and reports upregulation of the glucose transporter GLUT-1 in @Gene$ mutant tumours (Yun et al, 2009)
147	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter @Gene$ in K-Ras mutant @Disease$ (Yun et al, 2009)
148	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in @Gene$ mutant @Disease$ (Yun et al, 2009)
149	Current clinical data is sufficiently compelling that @Gene$ mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; @Disease$ and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)
150	Current clinical data is sufficiently compelling that @Gene$ mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with @Disease$ mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)
151	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-@Gene$ therapy is increasingly recommended in clinical practise (McNeill, 2008; @Disease$ and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)
152	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-@Gene$ therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with @Disease$ mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)
153	Although the clinical implications of non-hotspot @Gene$ mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of K-Ras mutations and quantitation of mutation burden in @Disease$ should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual K-Ras mutations.
154	Although the clinical implications of non-hotspot K-Ras mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of @Gene$ mutations and quantitation of mutation burden in @Disease$ should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual K-Ras mutations.
155	Although the clinical implications of non-hotspot K-Ras mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of K-Ras mutations and quantitation of mutation burden in @Disease$ should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual @Gene$ mutations.
156	Characterization of a novel oncogenic @Gene$ mutation in @Disease$
157	Oncogenic activation of the RAS/@Gene$ signaling pathway impairs the response of metastatic @Disease$ to anti-epidermal growth factor receptor antibody therapies
158	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic @Disease$ to anti-@Gene$ antibody therapies
159	Effect of common @Gene$ and N-RAS mutations on global gene expression in @Disease$ cell lines
160	Effect of common B-RAF and @Gene$ mutations on global gene expression in @Disease$ cell lines
161	The prognostic significance of @Gene$, p53, and @Disease$ mutations in colorectal carcinoma
162	The prognostic significance of @Gene$, p53, and APC mutations in @Disease$
163	The prognostic significance of K-ras, @Gene$, and @Disease$ mutations in colorectal carcinoma
164	The prognostic significance of K-ras, @Gene$, and APC mutations in @Disease$
165	Gene profiling of a @Disease$ cell line reveals similarities and unique signatures among @Gene$ response, N-ras-activating mutations, and coculture with bone marrow stromal cells
166	Gene profiling of a @Disease$ cell line reveals similarities and unique signatures among IL-6 response, @Gene$-activating mutations, and coculture with bone marrow stromal cells
167	Mutations of the @Gene$ gene in human @Disease$
168	Mutation analysis in @Disease$: functional and structural characterization of the @Gene$ p.Lys117Arg mutation
169	Wild-type @Gene$ is required for response to panitumumab or cetuximab in metastatic @Disease$
170	Recurrent @Gene$ codon 146 mutations in human @Disease$
171	@Gene$ mutations and treatment outcome in @Disease$ patients receiving exclusive fluoropyrimidine therapy
172	Association of @Gene$ mutational status and clinical outcomes in patients with metastatic @Disease$ receiving panitumumab alone
173	Genome profiling of @Disease$: frequent alterations of RAS and @Gene$ genes
174	@Gene$ mutations and benefit from cetuximab in advanced @Disease$
175	Expression of @Gene$ and amphiregulin and K-ras mutation status predict disease control in metastatic @Disease$ patients treated with cetuximab
176	Expression of epiregulin and @Gene$ and K-ras mutation status predict disease control in metastatic @Disease$ patients treated with cetuximab
177	Expression of epiregulin and amphiregulin and @Gene$ mutation status predict disease control in metastatic @Disease$ patients treated with cetuximab
178	Mutations of @Disease$, @Gene$, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas
179	Mutations of @Disease$, K-ras, and @Gene$ are associated with specific chromosomal aberrations in colorectal adenocarcinomas
180	Mutations of APC, @Gene$, and p53 are associated with specific chromosomal aberrations in @Disease$
181	Mutations of APC, K-ras, and @Gene$ are associated with specific chromosomal aberrations in @Disease$
182	@Gene$ mutation status is predictive of response to cetuximab therapy in @Disease$
183	@Gene$ codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic @Disease$
184	KRAS codon 61, 146 and @Gene$ mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic @Disease$
185	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in @Gene$ codon 12 and 13 wild-type metastatic @Disease$
186	@Gene$ mutations are changingpractice in advanced @Disease$
187	Concurrent mutations of @Gene$ oncogene at codons 12 and 22 in @Disease$
188	A novel point mutation at codon 146 of the @Gene$ gene in a human @Disease$ identified by the polymerase chain reaction
189	@Gene$ mutations in human @Disease$
190	Understanding the predictive role of @Gene$ for epidermal growth factor receptor-targeted therapies in @Disease$
191	Understanding the predictive role of K-ras for @Gene$-targeted therapies in @Disease$
192	Mutations in @Disease$, @Gene$, and p53-alternative genetic pathways to colorectal cancer
193	Mutations in @Disease$, Kirsten-ras, and @Gene$-alternative genetic pathways to colorectal cancer
194	Mutations in APC, @Gene$, and p53-alternative genetic pathways to @Disease$
195	Mutations in APC, Kirsten-ras, and @Gene$-alternative genetic pathways to @Disease$
196	Setting future standards for @Gene$ testing in @Disease$
197	@Gene$ is a @Disease$ promoter target in initiated cells that express oncogenic Ras
198	Different types of @Gene$ mutations are conversely associated with overall survival in patients with @Disease$
199	@Gene$ mutation profile in @Disease$ and novel mutation-internal tandem duplication in KRAS
200	@Disease$ cells with mutant @Gene$ suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2
201	@Disease$ cells with mutant K-ras suppress @Gene$ activity by MEK-dependent induction of MAP kinase phosphatase-2
202	@Disease$ cells with mutant K-ras suppress ERK activity by @Gene$-dependent induction of MAP kinase phosphatase-2
203	@Disease$ contributes to the development of @Gene$ pathway mutations in tumor cells
204	Glucose deprivation contributes to the development of @Gene$ pathway mutations in @Disease$ cells
205	Active Ras, where @Disease$-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-@Gene$-MEK-ERK-MAP kinase signalling pathway.
206	Active Ras, where @Disease$-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-RAF-@Gene$-ERK-MAP kinase signalling pathway.
207	Active Ras, where @Disease$-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-RAF-MEK-@Gene$-MAP kinase signalling pathway.
208	A novel @Gene$ gene copy number assay was designed as described in Materials and Methods and used to screen genomic DNA samples extracted from 96 paired normal (N) and @Disease$ (T) tissues
209	Representative @Disease$ sections (C) without and (D) with a @Gene$ gene amplification are illustrated.
210	Relationship of increased @Gene$ gene copy number, prognosis and response to chemotherapy in patients with metastatic @Disease$
211	Increased @Gene$ gene copy number (AURKA-CN) has been reported in metastatic @Disease$ (mCRC), with unknown relationship to clinical outcome
212	Increased Aurora kinase A gene copy number (@Gene$-CN) has been reported in metastatic @Disease$ (mCRC), with unknown relationship to clinical outcome
213	We correlated increased @Gene$-CN in mCRC @Disease$ with KRAS mutation status, overall and progression-free survival (OS, PFS).
214	We correlated increased AURKA-CN in mCRC @Disease$ with @Gene$ mutation status, overall and progression-free survival (OS, PFS).
215	Sixty-one mCRC @Disease$ were analysed for @Gene$-CN using q-PCR, and KRAS mutation status by direct sequencing
216	Sixty-one mCRC @Disease$ were analysed for AURKA-CN using q-PCR, and @Gene$ mutation status by direct sequencing
217	In all, 68% of @Disease$ exhibited high @Gene$-CN, and 29% had a KRAS mutation, without correlation between the two
218	In all, 68% of @Disease$ exhibited high AURKA-CN, and 29% had a @Gene$ mutation, without correlation between the two
219	Patients with high @Gene$-CN @Disease$ had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among KRAS wild-type tumours (median OS not reached vs 18.8 months, P=0.003)
220	Patients with high @Gene$-CN tumours had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among KRAS wild-type @Disease$ (median OS not reached vs 18.8 months, P=0.003)
221	Patients with high AURKA-CN @Disease$ had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among @Gene$ wild-type tumours (median OS not reached vs 18.8 months, P=0.003)
222	Patients with high AURKA-CN tumours had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among @Gene$ wild-type @Disease$ (median OS not reached vs 18.8 months, P=0.003)
223	@Gene$-CN level did not affect outcomes among patients with KRAS mutant @Disease$.
224	AURKA-CN level did not affect outcomes among patients with @Gene$ mutant @Disease$.
225	Increased @Gene$-CN is common in mCRC @Disease$ and is associated with longer OS and longer PFS during chemotherapy, particularly in KRAS wild-type tumours.
226	Increased @Gene$-CN is common in mCRC tumours and is associated with longer OS and longer PFS during chemotherapy, particularly in KRAS wild-type @Disease$.
227	Increased AURKA-CN is common in mCRC @Disease$ and is associated with longer OS and longer PFS during chemotherapy, particularly in @Gene$ wild-type tumours.
228	Increased AURKA-CN is common in mCRC tumours and is associated with longer OS and longer PFS during chemotherapy, particularly in @Gene$ wild-type @Disease$.
229	@Gene$ (AURKA) (also known as Aurora-2, BTAK/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from @Disease$
230	Aurora kinase A (@Gene$) (also known as Aurora-2, BTAK/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from @Disease$
231	Aurora kinase A (AURKA) (also known as @Gene$, BTAK/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from @Disease$
232	Aurora kinase A (AURKA) (also known as Aurora-2, @Gene$/STK15) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from @Disease$
233	Aurora kinase A (AURKA) (also known as Aurora-2, BTAK/@Gene$) regulates mitotic entry, centrosome maturation, bipolar spindle assembly, chromosome alignment, cytokinesis and exit from @Disease$
234	Aberrations in the function of @Gene$ can result in abnormal cell division and @Disease$ due to losses or gains of whole chromosomes
235	In @Disease$ (CRC), @Gene$ protein overexpression and amplification have been frequently observed
236	were the first to report overexpression of @Gene$ mRNA in >50% of @Disease$
237	The group led by was the first to demonstrate an increase in @Gene$ gene copy number (AURKA-CN) in 29% of a small sample of @Disease$
238	The group led by was the first to demonstrate an increase in AURKA gene copy number (@Gene$-CN) in 29% of a small sample of @Disease$
239	Recently, the group led by reported increased @Gene$-CN in 32% of @Disease$ samples and particularly in higher stage tumours, suggesting that AURKA may have a role in tumour progression
240	Recently, the group led by reported increased @Gene$-CN in 32% of CRC tumour samples and particularly in higher @Disease$, suggesting that AURKA may have a role in tumour progression
241	Recently, the group led by reported increased @Gene$-CN in 32% of CRC tumour samples and particularly in higher stage tumours, suggesting that AURKA may have a role in @Disease$ progression
242	Recently, the group led by reported increased AURKA-CN in 32% of @Disease$ samples and particularly in higher stage tumours, suggesting that @Gene$ may have a role in tumour progression
243	Recently, the group led by reported increased AURKA-CN in 32% of CRC tumour samples and particularly in higher @Disease$, suggesting that @Gene$ may have a role in tumour progression
244	Recently, the group led by reported increased AURKA-CN in 32% of CRC tumour samples and particularly in higher stage tumours, suggesting that @Gene$ may have a role in @Disease$ progression
245	The goal in this study was to assess the frequency of increased @Gene$-CN in @Disease$ tissues of patients with metastatic CRC (mCRC) and correlate this finding with progression-free survival (PFS), overall survival (OS), and KRAS mutation status.
246	The goal in this study was to assess the frequency of increased AURKA-CN in @Disease$ tissues of patients with metastatic CRC (mCRC) and correlate this finding with progression-free survival (PFS), overall survival (OS), and @Gene$ mutation status.
247	We analysed 61 consecutive mCRC @Disease$ samples submitted between 2006 and 2009 to the Fox Chase Cancer Center (FCCC) molecular genetic facility for evaluation of @Gene$ mutation status, with remaining tissue available for AURKA-CN evaluation
248	We analysed 61 consecutive mCRC @Disease$ samples submitted between 2006 and 2009 to the Fox Chase Cancer Center (FCCC) molecular genetic facility for evaluation of KRAS mutation status, with remaining tissue available for @Gene$-CN evaluation
249	We analysed 61 consecutive mCRC tumour samples submitted between 2006 and 2009 to the Fox Chase @Disease$ Center (FCCC) molecular genetic facility for evaluation of @Gene$ mutation status, with remaining tissue available for AURKA-CN evaluation
250	We analysed 61 consecutive mCRC tumour samples submitted between 2006 and 2009 to the Fox Chase @Disease$ Center (FCCC) molecular genetic facility for evaluation of KRAS mutation status, with remaining tissue available for @Gene$-CN evaluation
251	Most of the patients had their @Disease$ samples submitted by their treating oncologist for @Gene$ mutation status evaluation after the test became routinely used in clinical practice (2008)
252	Of the 61 tissue samples obtained for @Gene$-CN analysis, 62% originated from primary @Disease$, while 38% originated from metastatic sites
253	For patients with high @Gene$-CN @Disease$, the median PFS on first-line chemotherapy was 11.5 months vs 7.7 months for patients with low AURKA-CN tumours (HR=0.56, 95% CI: 0.28-1.1, P=0.094; Figure 3A)
254	For patients with high @Gene$-CN tumours, the median PFS on first-line chemotherapy was 11.5 months vs 7.7 months for patients with @Disease$ (HR=0.56, 95% CI: 0.28-1.1, P=0.094; Figure 3A)
255	Among patients with @Disease$, those with high @Gene$-CN tumours had prolonged PFS compared with patients with low AURKA-CN tumours (HR=0.43, 95% CI: 0.19-0.94, P=0.04; Figure 3B)
256	Among patients with KRAS wild-type tumours, those with high @Gene$-CN @Disease$ had prolonged PFS compared with patients with low AURKA-CN tumours (HR=0.43, 95% CI: 0.19-0.94, P=0.04; Figure 3B)
257	Among patients with KRAS wild-type tumours, those with high @Gene$-CN tumours had prolonged PFS compared with patients with @Disease$ (HR=0.43, 95% CI: 0.19-0.94, P=0.04; Figure 3B)
258	Conversely, PFS did not differ by @Gene$-CN expression among patients with KRAS mutant @Disease$ (HR=1.06, 95% CI: 0.28-3.93, P=0.93), although the small sample size limits definitive conclusions regarding this population.
259	Conversely, PFS did not differ by AURKA-CN expression among patients with @Gene$ mutant @Disease$ (HR=1.06, 95% CI: 0.28-3.93, P=0.93), although the small sample size limits definitive conclusions regarding this population.
260	No statistically significant difference in PFS was noted among patients with high vs low @Gene$-CN @Disease$ in the group overall (10.4 months vs 7.7 months; HR=0.54, 95% CI: 0.24-1.19, P=0.13; Figure 3C)
261	Table 3 outlines median PFS and HRs for high and low @Gene$-CN @Disease$ by KRAS mutational status and the use of cetuximab
262	Table 3 outlines median PFS and HRs for high and low AURKA-CN @Disease$ by @Gene$ mutational status and the use of cetuximab
263	Interestingly, among patients with @Disease$, high @Gene$-CN appeared to have the largest association with outcome among patients who did not receive cetuximab
264	A significantly longer OS was noted among patients with high vs low @Gene$-CN (median OS 48.6 months for patients with high AURKA-CN @Disease$ compared with 18.8 months for patients with low AURKA-CN tumours, HR=0.28, 95% CI: 0.10-0.73, P=0.01; Figure 4A)
265	A significantly longer OS was noted among patients with high vs low @Gene$-CN (median OS 48.6 months for patients with high AURKA-CN tumours compared with 18.8 months for patients with @Disease$, HR=0.28, 95% CI: 0.10-0.73, P=0.01; Figure 4A)
266	A significantly longer OS was noted among patients with high vs low AURKA-CN (median OS 48.6 months for patients with high @Gene$-CN @Disease$ compared with 18.8 months for patients with low AURKA-CN tumours, HR=0.28, 95% CI: 0.10-0.73, P=0.01; Figure 4A)
267	A significantly longer OS was noted among patients with high vs low AURKA-CN (median OS 48.6 months for patients with high @Gene$-CN tumours compared with 18.8 months for patients with @Disease$, HR=0.28, 95% CI: 0.10-0.73, P=0.01; Figure 4A)
268	In all, 1-year and 2-year survival were also longer among patients with high @Gene$-CN @Disease$ compared with those with low AURKA-CN tumours (1 year: 92.5% vs 82.2% P<0.001; 2 year: 80.9% vs 29.9%, P<0.001).
269	In all, 1-year and 2-year survival were also longer among patients with high @Gene$-CN tumours compared with those with low @Disease$ (1 year: 92.5% vs 82.2% P<0.001; 2 year: 80.9% vs 29.9%, P<0.001).
270	Similarly to PFS, the longer OS for patients with high @Gene$-CN @Disease$ was particularly pronounced in the KRAS wild-type patient population (Figure 4B)
271	Similarly to PFS, the longer OS for patients with high AURKA-CN @Disease$ was particularly pronounced in the @Gene$ wild-type patient population (Figure 4B)
272	Among patients with @Disease$, the median OS was not reached for high @Gene$-CN compared with 18.8 months for the group with low AURKA-CN tumours (HR=0.14, 95% CI: 0.038-0.514, P=0.003)
273	Among patients with KRAS wild-type tumours, the median OS was not reached for high @Gene$-CN compared with 18.8 months for the group with @Disease$ (HR=0.14, 95% CI: 0.038-0.514, P=0.003)
274	Similarly, increased 1-year and 2-year survival was seen among those patients with @Gene$ wild-type @Disease$ and high AURKA-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)
275	Similarly, increased 1-year and 2-year survival was seen among those patients with @Gene$ wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type @Disease$ and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)
276	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type @Disease$ and high @Gene$-CN compared with patients with KRAS wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)
277	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type @Disease$ and high AURKA-CN compared with patients with @Gene$ wild-type tumours and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)
278	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type @Disease$ and high AURKA-CN compared with patients with KRAS wild-type tumours and low @Gene$-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)
279	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high @Gene$-CN compared with patients with KRAS wild-type @Disease$ and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)
280	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with @Gene$ wild-type @Disease$ and low AURKA-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)
281	Similarly, increased 1-year and 2-year survival was seen among those patients with KRAS wild-type tumours and high AURKA-CN compared with patients with KRAS wild-type @Disease$ and low @Gene$-CN (1 year: 96% vs 75% P<0.0001; 2 year: 93% vs 28% P<0.0001)
282	IHC evaluation of @Gene$ @Disease$
283	Immunohistochemical evaluation of phosphorylated @Gene$ protein was performed on 27 available @Disease$ samples (20 with high AURKA-CN and 7 with low AURKA-CN)
284	Immunohistochemical evaluation of phosphorylated AURKA protein was performed on 27 available @Disease$ samples (20 with high @Gene$-CN and 7 with low AURKA-CN)
285	Immunohistochemical evaluation of phosphorylated AURKA protein was performed on 27 available @Disease$ samples (20 with high AURKA-CN and 7 with low @Gene$-CN)
286	Among the seven @Disease$ with low @Gene$-CN, none were positive for phosphorylated T-288
287	However, among the 20 @Disease$ with high @Gene$-CN, 9 were found to have positive staining (P=0.06 for difference between high and low AURKA-CN tumours)
288	However, among the 20 tumours with high @Gene$-CN, 9 were found to have positive staining (P=0.06 for difference between high and low @Disease$)
289	The groups led by and reported increased @Gene$-CN in ~30% of @Disease$
290	The role of @Gene$ in tumourigenesis is well documented, although its utility as a prognostic marker is still under investigation in many @Disease$
291	reported a high expression of @Gene$ by AQUA to be a poor prognostic marker in patients with @Disease$
292	Similarly overexpression of @Gene$ was found to be a poor prognostic marker in @Disease$
293	Similarly to our findings, Lam and colleagues have demonstrated higher detection of the @Gene$ protein by IHC in low-grade (well or moderately differentiated) CRC samples compared with high-grade (poorly differentiated) @Disease$
294	Our data demonstrating increased PFS for patients with high @Gene$-CN @Disease$ support this hypothesis
295	The improved OS for patients with high @Gene$-CN was most pronounced in our study among patients with @Disease$
296	The improved response of patients with @Gene$ wild-type @Disease$ treated with anti-EGFR therapy has been well documented in the literature
297	The improved response of patients with KRAS wild-type @Disease$ treated with anti-@Gene$ therapy has been well documented in the literature
298	However in our study, among patients with @Disease$, the impact of high @Gene$-CN level was most pronounced in patients who did not receive cetuximab
299	Many groups have studied @Gene$ protein expression by IHC in CRC and other @Disease$
300	Moreover, our study is the first to demonstrate an association between high @Gene$-CN and improved clinical outcome among patients with mCRC receiving chemotherapy, with a more pronounced association noted among patients with @Disease$
301	@Gene$ expression is independently associated with chromosomal instability in @Disease$
302	Drosophila @Gene$ is required for centrosome maturation and actin-dependent asymmetric protein localization during @Disease$
303	A homologue of Drosophila @Gene$ is oncogenic and amplified in human @Disease$
304	@Gene$ mutations and benefit from cetuximab in advanced @Disease$
305	@Gene$ expression in @Disease$: correlations with clinicopathological features, p16 expression, and telomerase activity
306	Aurora kinase expression in @Disease$: correlations with clinicopathological features, @Gene$ expression, and telomerase activity
307	Expression of @Gene$ (but not Aurora B) is predictive of survival in @Disease$
308	Expression of Aurora A (but not @Gene$) is predictive of survival in @Disease$
309	High copy amplification of the @Gene$ gene is associated with chromosomal instability phenotype in human @Disease$
310	Quantitation of @Gene$ gene copy number in urine sediments and @Disease$ detection
311	Effects of DNAzymes targeting @Gene$ on the growth of human @Disease$
312	Overexpression of @Gene$ kinase (AURKB) in primary non-small cell lung @Disease$ is frequent, generally driven from one allele, and correlates with the level of genetic instability
313	Overexpression of aurora B kinase (@Gene$) in primary non-small cell lung @Disease$ is frequent, generally driven from one allele, and correlates with the level of genetic instability
314	@Gene$ is a predictive factor for the aggressive recurrence of @Disease$ after curative hepatectomy
315	Inhibition of @Gene$ suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal @Disease$ cells
316	@Gene$ expression correlates with aggressive behaviour in @Disease$
317	Copy number increase of @Gene$ in @Disease$: a correlation with tumor progression
318	Copy number increase of @Gene$ in colorectal cancers: a correlation with @Disease$ progression
319	Progression-free survival (PFS) of metastatic @Disease$ patients receiving first-line and second-line chemotherapy by @Gene$-CN and KRAS mutation status
320	Progression-free survival (PFS) of metastatic @Disease$ patients receiving first-line and second-line chemotherapy by AURKA-CN and @Gene$ mutation status
321	Overall survival of metastatic @Disease$ patients by @Gene$-CN for entire cohort (A), the KRAS wild-type population (B) and the KRAS mutant population (C).
322	Overall survival of metastatic @Disease$ patients by AURKA-CN for entire cohort (A), the @Gene$ wild-type population (B) and the KRAS mutant population (C).
323	Overall survival of metastatic @Disease$ patients by AURKA-CN for entire cohort (A), the KRAS wild-type population (B) and the @Gene$ mutant population (C).
324	Immunohistochemistry staining for phosphorylated @Gene$ in metastatic @Disease$ samples
325	Interplay between @Gene$ and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of @Disease$
326	Interplay between BRCA1 and @Gene$ Regulates Epithelial Apicobasal Polarization and May Influence Risk of @Disease$
327	Genetic analysis identifies the @Gene$ gene as a modifier of the @Disease$ risk associated with BRCA1 gene mutation, while cell biological analysis of the protein product suggests a function in regulating development of the mammary gland.
328	Genetic analysis identifies the HMMR gene as a modifier of the @Disease$ risk associated with @Gene$ gene mutation, while cell biological analysis of the protein product suggests a function in regulating development of the mammary gland.
329	In @Gene$ mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing @Disease$ of basal-like type suggest that BRCA1 regulates stem/progenitor cell proliferation and differentiation
330	In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal breast tissue and increased risk of developing @Disease$ of basal-like type suggest that @Gene$ regulates stem/progenitor cell proliferation and differentiation
331	However, the function of @Gene$ in this process and its link to @Disease$ remain unknown
332	Here we depict a molecular mechanism involving @Gene$ and RHAMM that regulates apicobasal polarity and, when perturbed, may increase risk of @Disease$
333	Here we depict a molecular mechanism involving BRCA1 and @Gene$ that regulates apicobasal polarity and, when perturbed, may increase risk of @Disease$
334	Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility @Gene$ locus (encoding for RHAMM) that modifies @Disease$ risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively
335	Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for @Gene$) that modifies @Disease$ risk among BRCA1, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively
336	Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies @Disease$ risk among @Gene$, but probably not BRCA2, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively
337	Starting from complementary genetic analyses across families and populations, we identified common genetic variation at the low-penetrance susceptibility HMMR locus (encoding for RHAMM) that modifies @Disease$ risk among BRCA1, but probably not @Gene$, mutation carriers: n = 7,584, weighted hazard ratio (wHR) = 1.09 (95% CI 1.02-1.16), ptrend = 0.017; and n = 3,965, wHR = 1.04 (95% CI 0.94-1.16), ptrend = 0.43; respectively
338	Taken together, our data provide fundamental insight into apicobasal polarization through @Gene$ function, which may explain the expanded cell subsets and characteristic @Disease$ type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.
339	Taken together, our data provide fundamental insight into apicobasal polarization through @Gene$ function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic @Disease$ through perturbation of HMMR/RHAMM.
340	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic @Disease$ type accompanying @Gene$ mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/RHAMM.
341	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic @Disease$ type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of @Gene$/RHAMM.
342	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic @Disease$ type accompanying BRCA1 mutation, while also linking this process to sporadic breast cancer through perturbation of HMMR/@Gene$.
343	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying @Gene$ mutation, while also linking this process to sporadic @Disease$ through perturbation of HMMR/RHAMM.
344	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic @Disease$ through perturbation of @Gene$/RHAMM.
345	Taken together, our data provide fundamental insight into apicobasal polarization through BRCA1 function, which may explain the expanded cell subsets and characteristic tumor type accompanying BRCA1 mutation, while also linking this process to sporadic @Disease$ through perturbation of HMMR/@Gene$.
346	Mutations in two genes that were initially identified as predisposing carriers to early-onset @Disease$, @Gene$ and BRCA2, cause similar perturbations in cellular responses to DNA damage but predispose carriers to distinct tumor types
347	Mutations in two genes that were initially identified as predisposing carriers to early-onset @Disease$, BRCA1 and @Gene$, cause similar perturbations in cellular responses to DNA damage but predispose carriers to distinct tumor types
348	Mutations in two genes that were initially identified as predisposing carriers to early-onset breast cancer, @Gene$ and BRCA2, cause similar perturbations in cellular responses to DNA damage but predispose carriers to distinct @Disease$ types
349	Mutations in two genes that were initially identified as predisposing carriers to early-onset breast cancer, BRCA1 and @Gene$, cause similar perturbations in cellular responses to DNA damage but predispose carriers to distinct @Disease$ types
350	We have used genetic analyses of affected families to uncover additional genetic variation that is linked to the risk of developing @Disease$ for carriers of @Gene$ mutations
351	Our findings provide new insights into the mechanism through which @Gene$ may promote commitment of initially bipotent mammary cells towards the luminal lineage, and how loss of this function may predispose cells to become @Disease$ of a basal-like type.
352	The common pathological features of @Disease$ arising in breast cancer 1, early onset (@Gene$) gene mutation carriers, including the basal-like phenotype and ER negativity, led to the proposition that BRCA1 function regulates stem/progenitor cell proliferation and differentiation
353	The common pathological features of @Disease$ arising in breast cancer 1, early onset (BRCA1) gene mutation carriers, including the basal-like phenotype and ER negativity, led to the proposition that @Gene$ function regulates stem/progenitor cell proliferation and differentiation
354	The common pathological features of breast tumors arising in @Disease$ 1, early onset (@Gene$) gene mutation carriers, including the basal-like phenotype and ER negativity, led to the proposition that BRCA1 function regulates stem/progenitor cell proliferation and differentiation
355	The common pathological features of breast tumors arising in @Disease$ 1, early onset (BRCA1) gene mutation carriers, including the basal-like phenotype and ER negativity, led to the proposition that @Gene$ function regulates stem/progenitor cell proliferation and differentiation
356	Expanded luminal progenitor populations have also been detected in breast tissue from @Gene$ mutation carriers and, subsequently, proposed as the target of transformation leading to basal-like @Disease$
357	@Gene$ is the ortholog of a candidate low-penetrance @Disease$ susceptibility gene product (RHAMM, HMMR gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis
358	@Gene$ is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (RHAMM, HMMR gene) whose over-expression in @Disease$ is associated with poor prognosis and early age at diagnosis
359	Xrhamm is the ortholog of a candidate low-penetrance @Disease$ susceptibility gene product (@Gene$, HMMR gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis
360	Xrhamm is the ortholog of a candidate low-penetrance @Disease$ susceptibility gene product (RHAMM, @Gene$ gene) whose over-expression in tumors is associated with poor prognosis and early age at diagnosis
361	Xrhamm is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (@Gene$, HMMR gene) whose over-expression in @Disease$ is associated with poor prognosis and early age at diagnosis
362	Xrhamm is the ortholog of a candidate low-penetrance breast cancer susceptibility gene product (RHAMM, @Gene$ gene) whose over-expression in @Disease$ is associated with poor prognosis and early age at diagnosis
363	Conversely, loss of @Gene$ function might impair structural cues of terminal differentiation and, consequently, increase risk of @Disease$ characterized by the basal-like tumor type
364	Conversely, loss of @Gene$ function might impair structural cues of terminal differentiation and, consequently, increase risk of breast cancer characterized by the basal-like @Disease$ type
365	Common Genetic Variation in @Disease$ Risk among @Gene$ Mutation Carriers
366	Although @Gene$ and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of @Disease$ arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes
367	Although @Gene$ and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that @Disease$ may occur through perturbation of shared and distinct biological processes
368	Although BRCA1 and @Gene$ function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of @Disease$ arising in BRCA1 and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes
369	Although BRCA1 and @Gene$ function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and BRCA2 mutation carriers suggest that @Disease$ may occur through perturbation of shared and distinct biological processes
370	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of @Disease$ arising in @Gene$ and BRCA2 mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes
371	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of @Disease$ arising in BRCA1 and @Gene$ mutation carriers suggest that carcinogenesis may occur through perturbation of shared and distinct biological processes
372	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in @Gene$ and BRCA2 mutation carriers suggest that @Disease$ may occur through perturbation of shared and distinct biological processes
373	Although BRCA1 and BRCA2 function coordinately during DNA damage response, genomic, transcriptomic, molecular, and pathological features of breast tumors arising in BRCA1 and @Gene$ mutation carriers suggest that @Disease$ may occur through perturbation of shared and distinct biological processes
374	Previous analysis of candidate genomic regions using a linkage approach suggested specific modification of @Disease$ risk among @Gene$ mutation carriers by common genetic variation at chromosome 5q33-34
375	Common @Disease$-predisposition alleles may differentially modify breast cancer risk among @Gene$ and BRCA2 mutation carriers
376	Common @Disease$-predisposition alleles may differentially modify breast cancer risk among BRCA1 and @Gene$ mutation carriers
377	Common breast cancer-predisposition alleles may differentially modify @Disease$ risk among @Gene$ and BRCA2 mutation carriers
378	Common breast cancer-predisposition alleles may differentially modify @Disease$ risk among BRCA1 and @Gene$ mutation carriers
379	To complement the linkage approach, we evaluated the effect of common @Gene$ genetic variation on @Disease$ risk in BRCA1 and BRCA2 mutation carriers
380	To complement the linkage approach, we evaluated the effect of common HMMR genetic variation on @Disease$ risk in @Gene$ and BRCA2 mutation carriers
381	To complement the linkage approach, we evaluated the effect of common HMMR genetic variation on @Disease$ risk in BRCA1 and @Gene$ mutation carriers
382	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of @Gene$ (CIMBA) detected significant modification of @Disease$ risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
383	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of @Disease$ risk by @Gene$ rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
384	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of @Disease$ risk by HMMR rs299290 variant among @Gene$, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
385	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of @Disease$ risk by HMMR rs299290 variant among BRCA1, but not @Gene$, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
386	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of @Disease$ risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: @Gene$ mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
387	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of @Disease$ risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, @Gene$ proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; BRCA2 mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
388	Following a pilot study in Italy and Spain, analysis of carriers (n = 11,609) collected through 24 study groups participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) detected significant modification of @Disease$ risk by HMMR rs299290 variant among BRCA1, but not BRCA2, mutation carriers: BRCA1 mutation carriers n = 7,584, Cox proportional-hazards regression model, hazard ratio (HR) = 1.08 (95% confidence interval (CI) 1.02-1.13), ptrend = 0.004 (p 2df = 0.014), in the same direction as originally detected in Ashkenazi Jewish populations; @Gene$ mutation carriers n = 3,965, HR = 1.03 (95% CI 0.96-1.10), ptrend = 0.42 (p 2df = 0.67)
389	Effect of @Gene$ rs299290 variation on @Disease$ risk among BRCA1 and BRCA2 mutation carriers.
390	Effect of HMMR rs299290 variation on @Disease$ risk among @Gene$ and BRCA2 mutation carriers.
391	Effect of HMMR rs299290 variation on @Disease$ risk among BRCA1 and @Gene$ mutation carriers.
392	First, since prophylactic oophorectomy reduces the risk of @Disease$ in @Gene$ mutation carriers by up to 50%, we included this observation as a time-dependent covariate in the analysis, and a significant association similar to the one shown above was revealed: HR = 1.09 (95% CI 1.03-1.16), ptrend = 4.5x10-4
393	While studies have identified low-penetrance alleles that associate with @Disease$ risk in carriers of @Gene$ mutations and carriers of BRCA2 mutations, specificities have also been detected
394	While studies have identified low-penetrance alleles that associate with @Disease$ risk in carriers of BRCA1 mutations and carriers of @Gene$ mutations, specificities have also been detected
395	Here, the results of linkage and association studies support a potential, specific genetic interaction between @Gene$ and HMMR (high- and low-penetrance mutations, respectively), which could highlight a BRCA1-RHAMM function altered in familial and sporadic @Disease$.
396	Here, the results of linkage and association studies support a potential, specific genetic interaction between BRCA1 and @Gene$ (high- and low-penetrance mutations, respectively), which could highlight a BRCA1-RHAMM function altered in familial and sporadic @Disease$.
397	Here, the results of linkage and association studies support a potential, specific genetic interaction between BRCA1 and HMMR (high- and low-penetrance mutations, respectively), which could highlight a @Gene$-RHAMM function altered in familial and sporadic @Disease$.
398	Here, the results of linkage and association studies support a potential, specific genetic interaction between BRCA1 and HMMR (high- and low-penetrance mutations, respectively), which could highlight a BRCA1-@Gene$ function altered in familial and sporadic @Disease$.
399	@Disease$ arising in @Gene$ mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive
400	@Disease$ arising in BRCA1 mutation carriers are typically @Gene$-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are ER-positive
401	@Disease$ arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in @Gene$ mutation carriers and sporadic cases are ER-positive
402	@Disease$ arising in BRCA1 mutation carriers are typically ER-negative, whereas most tumors in BRCA2 mutation carriers and sporadic cases are @Gene$-positive
403	Breast tumors arising in @Gene$ mutation carriers are typically ER-negative, whereas most @Disease$ in BRCA2 mutation carriers and sporadic cases are ER-positive
404	Breast tumors arising in BRCA1 mutation carriers are typically @Gene$-negative, whereas most @Disease$ in BRCA2 mutation carriers and sporadic cases are ER-positive
405	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most @Disease$ in @Gene$ mutation carriers and sporadic cases are ER-positive
406	Breast tumors arising in BRCA1 mutation carriers are typically ER-negative, whereas most @Disease$ in BRCA2 mutation carriers and sporadic cases are @Gene$-positive
407	Given the evidence above, we next evaluated whether @Gene$ variation was associated with ER @Disease$ status in BRCA1 and/or BRCA2 mutation carriers
408	Given the evidence above, we next evaluated whether HMMR variation was associated with @Gene$ @Disease$ status in BRCA1 and/or BRCA2 mutation carriers
409	Given the evidence above, we next evaluated whether HMMR variation was associated with ER @Disease$ status in @Gene$ and/or BRCA2 mutation carriers
410	Given the evidence above, we next evaluated whether HMMR variation was associated with ER @Disease$ status in BRCA1 and/or @Gene$ mutation carriers
411	In data provided by several CIMBA groups (Text S1), no @Gene$-positive @Disease$ were observed among rare rs299290 homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)
412	In data provided by several CIMBA groups (Text S1), no ER-positive @Disease$ were observed among rare rs299290 homozygotes in @Gene$ mutation carriers (p interaction = 0.006), whereas this bias was not observed in BRCA2 mutation carriers (p interaction = 0.95) (Table S4)
413	In data provided by several CIMBA groups (Text S1), no ER-positive @Disease$ were observed among rare rs299290 homozygotes in BRCA1 mutation carriers (p interaction = 0.006), whereas this bias was not observed in @Gene$ mutation carriers (p interaction = 0.95) (Table S4)
414	That is, despite the expected differences in the frequency of @Disease$ types between the two sets of carriers, heterogeneity was observed in the distribution of rs299290 genotypes in @Gene$, but not BRCA2, mutation carriers
415	That is, despite the expected differences in the frequency of @Disease$ types between the two sets of carriers, heterogeneity was observed in the distribution of rs299290 genotypes in BRCA1, but not @Gene$, mutation carriers
416	The growth of nonmalignant human mammary epithelial cells, such as MCF10A and @Gene$3522 S1, within three-dimensional cultures containing reconstituted basement membrane (rBM) recapitulates aspects of the terminal differentiation of mammary @Disease$, including apicobasal polarization, growth arrest, and milk production
417	The growth of nonmalignant human mammary epithelial cells, such as MCF10A and @Gene$3522 S1, within three-dimensional cultures containing reconstituted basement membrane (rBM) recapitulates aspects of the terminal differentiation of mammary luminal epithelia, including apicobasal polarization, @Disease$, and milk production
418	Thus, loss of @Gene$ function may impair polarization by altering intracellular cytoskeletal organization, resulting in intermediate filament content consistent with the characteristic basal-like @Disease$ type.
419	While @Disease$ does not preclude the formation of a functional luminal layer, the cytoskeletal structure within luminal epithelia from @Gene$ mutation carriers might be compromised
420	While BRCA1 haploinsufficiency does not preclude the formation of a functional luminal layer, the cytoskeletal structure within @Disease$ from @Gene$ mutation carriers might be compromised
421	Importantly, both proteasome inhibition and @Gene$ depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in @Disease$ cell lines derived from BRCA1 mutation carriers
422	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of @Gene$ (Figure S7), which is also consistent with observed RHAMM over-expression in @Disease$ cell lines derived from BRCA1 mutation carriers
423	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed @Gene$ over-expression in @Disease$ cell lines derived from BRCA1 mutation carriers
424	Importantly, both proteasome inhibition and BRCA1 depletion increased the abundance of RHAMM (Figure S7), which is also consistent with observed RHAMM over-expression in @Disease$ cell lines derived from @Gene$ mutation carriers
425	Consistent with previous reports, total @Gene$ decorates all microtubule structures throughout @Disease$
426	Threonine 703 (T703) is an evolutionarily conserved phosphorylated residue in @Gene$ similar to a @Disease$ kinase Ipl1p site
427	Threonine 703 (T703) is an evolutionarily conserved phosphorylated residue in RHAMM similar to a @Disease$ kinase @Gene$ site
428	pT703-@Gene$ Expression in BRCA1 Mutant @Disease$; A Mechanistic Model for Polarization and Increased Risk of Breast Cancer
429	pT703-@Gene$ Expression in BRCA1 Mutant Breast Cancer Cells and Tumors; A Mechanistic Model for Polarization and Increased Risk of @Disease$
430	pT703-RHAMM Expression in @Gene$ Mutant @Disease$; A Mechanistic Model for Polarization and Increased Risk of Breast Cancer
431	pT703-RHAMM Expression in @Gene$ Mutant Breast Cancer Cells and Tumors; A Mechanistic Model for Polarization and Increased Risk of @Disease$
432	To evaluate the link with @Disease$, pT703-@Gene$ immunochemistry was performed in BRCA1 mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors
433	To evaluate the link with @Disease$, pT703-RHAMM immunochemistry was performed in @Gene$ mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors
434	To evaluate the link with carcinogenesis, pT703-@Gene$ immunochemistry was performed in BRCA1 mutant @Disease$ cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors
435	To evaluate the link with carcinogenesis, pT703-@Gene$ immunochemistry was performed in BRCA1 mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary @Disease$
436	To evaluate the link with carcinogenesis, pT703-RHAMM immunochemistry was performed in @Gene$ mutant @Disease$ cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary breast tumors
437	To evaluate the link with carcinogenesis, pT703-RHAMM immunochemistry was performed in @Gene$ mutant breast cancer cells, HCC1937 line, their wild-type reconstituted counterparts, and in primary @Disease$
438	Subsequently, high expression of @Gene$ was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative @Disease$, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)
439	Subsequently, high expression of @Gene$ was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive @Disease$, respectively (Figure 7B)
440	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of @Gene$ mutation carriers and sporadic ER-negative @Disease$, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)
441	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of @Gene$ mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive @Disease$, respectively (Figure 7B)
442	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic @Gene$-negative @Disease$, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)
443	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic @Gene$-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic ER-positive @Disease$, respectively (Figure 7B)
444	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative @Disease$, respectively, but in 36% (n = 5) and 30% (n = 10) of @Gene$ mutation carriers and sporadic ER-positive tumors, respectively (Figure 7B)
445	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative @Disease$, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic @Gene$-positive tumors, respectively (Figure 7B)
446	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of @Gene$ mutation carriers and sporadic ER-positive @Disease$, respectively (Figure 7B)
447	Subsequently, high expression of pT703-RHAMM was scored in 58% (n = 11) and 50% (n = 4) of BRCA1 mutation carriers and sporadic ER-negative tumors, respectively, but in 36% (n = 5) and 30% (n = 10) of BRCA2 mutation carriers and sporadic @Gene$-positive @Disease$, respectively (Figure 7B)
448	Although this dataset is limited, the results support the indication of an interplay between @Gene$ and RHAMM, which is altered in @Disease$.
449	Although this dataset is limited, the results support the indication of an interplay between BRCA1 and @Gene$, which is altered in @Disease$.
450	pT703-@Gene$ expression in BRCA1 mutant @Disease$ cells and tumors.
451	pT703-@Gene$ expression in BRCA1 mutant breast cancer cells and @Disease$.
452	pT703-RHAMM expression in @Gene$ mutant @Disease$ cells and tumors.
453	pT703-RHAMM expression in @Gene$ mutant breast cancer cells and @Disease$.
454	(B) Results of @Gene$ staining scores in primary @Disease$ with different BRCA1/2 mutation and ER status
455	(B) Results of pT703-RHAMM staining scores in primary @Disease$ with different @Gene$/2 mutation and ER status
456	(B) Results of pT703-RHAMM staining scores in primary @Disease$ with different BRCA1/2 mutation and @Gene$ status
457	This model is consistent with reduced expression of @Gene$, TPX2, and HMMR, but to a lesser extent BRCA1, with polarization and @Disease$ of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)
458	This model is consistent with reduced expression of AURKA, @Gene$, and HMMR, but to a lesser extent BRCA1, with polarization and @Disease$ of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)
459	This model is consistent with reduced expression of AURKA, TPX2, and @Gene$, but to a lesser extent BRCA1, with polarization and @Disease$ of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)
460	This model is consistent with reduced expression of AURKA, TPX2, and HMMR, but to a lesser extent @Gene$, with polarization and @Disease$ of nonmalignant mammary epithelial cells, as measured by gene expression profiling (Figure S11A)
461	Deviation from this pathway, through loss of @Gene$ function or augmentation of microtubule-associated factors, may impair terminal differentiation of @Disease$ and promote tumorigenesis
462	Consistently, @Gene$ over-expression might be detectable as early as the transition from normal breast tissue to @Disease$ (Figure S11B)
463	We have investigated gene and protein interactions in a centrosome-cantered module, including @Gene$/BRCA1 and HMMR/RHAMM, across biological systems ranging from @Disease$ risk estimates to cellular phenotypes and cytoskeletal structures
464	We have investigated gene and protein interactions in a centrosome-cantered module, including BRCA1/@Gene$ and HMMR/RHAMM, across biological systems ranging from @Disease$ risk estimates to cellular phenotypes and cytoskeletal structures
465	We have investigated gene and protein interactions in a centrosome-cantered module, including BRCA1/BRCA1 and @Gene$/RHAMM, across biological systems ranging from @Disease$ risk estimates to cellular phenotypes and cytoskeletal structures
466	We have investigated gene and protein interactions in a centrosome-cantered module, including BRCA1/BRCA1 and HMMR/@Gene$, across biological systems ranging from @Disease$ risk estimates to cellular phenotypes and cytoskeletal structures
467	Accordingly, a common candidate @Disease$-predisposition allele in @Gene$, originally identified in an Ashkenazi Jewish study, may specifically modify breast cancer risk among BRCA1 mutation carriers
468	Accordingly, a common candidate @Disease$-predisposition allele in HMMR, originally identified in an Ashkenazi Jewish study, may specifically modify breast cancer risk among @Gene$ mutation carriers
469	Accordingly, a common candidate breast cancer-predisposition allele in @Gene$, originally identified in an Ashkenazi Jewish study, may specifically modify @Disease$ risk among BRCA1 mutation carriers
470	Accordingly, a common candidate breast cancer-predisposition allele in HMMR, originally identified in an Ashkenazi Jewish study, may specifically modify @Disease$ risk among @Gene$ mutation carriers
471	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding @Gene$ and HMMR) may frequently influence risk of @Disease$ and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and TPX2 loci
472	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and @Gene$) may frequently influence risk of @Disease$ and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and TPX2 loci
473	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of @Disease$ and, notably, includes variants in @Gene$-a proposed HMMR homolog -TUBG1, and TPX2 loci
474	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of @Disease$ and, notably, includes variants in TACC3-a proposed @Gene$ homolog -TUBG1, and TPX2 loci
475	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of @Disease$ and, notably, includes variants in TACC3-a proposed HMMR homolog -@Gene$, and TPX2 loci
476	A recent report has suggested that common genetic variation in genes encoding for centrosome pathway components (excluding AURKA and HMMR) may frequently influence risk of @Disease$ and, notably, includes variants in TACC3-a proposed HMMR homolog -TUBG1, and @Gene$ loci
477	A unifying mechanism of @Disease$ linked to @Gene$ loss-of-function should provide a comprehensive explanation for the observed accumulation of stem and luminal progenitor cells, and for the characteristic pathological features of the corresponding tumors
478	A unifying mechanism of breast carcinogenesis linked to @Gene$ loss-of-function should provide a comprehensive explanation for the observed accumulation of stem and luminal progenitor cells, and for the characteristic pathological features of the corresponding @Disease$
479	Should @Gene$ function(s) promote this transition in mammary stem/progenitor cells, impaired luminal differentiation in BRCA1 mutation carriers and a propensity to develop basal-like @Disease$ with elevated proliferative capacity would be expected
480	Should BRCA1 function(s) promote this transition in mammary stem/progenitor cells, impaired luminal differentiation in @Gene$ mutation carriers and a propensity to develop basal-like @Disease$ with elevated proliferative capacity would be expected
481	Accordingly, @Gene$ depletion increases the clonogenic potential of mammary @Disease$, while a BRCA1 S308A mutant alters embryonic stem cell differentiation
482	Accordingly, BRCA1 depletion increases the clonogenic potential of mammary @Disease$, while a @Gene$ S308A mutant alters embryonic stem cell differentiation
483	A key question remains regarding the significance of @Gene$ function to stem/progenitor differentiation and @Disease$
484	Examination of histologically normal breast tissue in @Gene$ mutation carriers revealed cellular foci expressing stem cell markers and lacking cytoskeletal structures characteristic of @Disease$
485	Thus, @Gene$ dose or mutation type may distinctly affect the tissue architecture and function, leading to differences in the accumulation of stem or progenitor cells, and the resulting @Disease$ type
486	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; @Gene$ 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses @Disease$"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"
487	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; @Gene$ 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for @Disease$ Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"
488	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; @Gene$ 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le @Disease$ du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"
489	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; @Gene$ 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""@Disease$""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"
490	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; @Gene$ 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National @Disease$ Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"
491	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; @Gene$ 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense @Disease$ Research Program (05/0612), the Eileen Stein Jacoby Fund, the Breast Cancer Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"
492	"This work was funded by the Spanish Ministries of Health, and Science ane Innovation (CB07/02/2005; @Gene$ 08/1120, 08/1359, 08/1635, and 09/02483; RTICCC RD06/0020/1060 and RD06/0020/0028; Transversal Action Against Cancer; the Spanish Biomedical Research Centre Networks for Epidemiology and Public Health, and Rare Diseases; and the ""Ramon y Cajal"" Young Investigator Program), the Spanish National Society of Medical Oncology (2010), the Spanish Association Against Cancer (AECC 2010), the AGAUR Catalan Government Agency (2009SGR1489 and 2009SGR293; and the Beatriu Pinos Postdoctoral Program), the Ramon Areces Foundation (XV), the ""Roses Contra el Cancer"" Foundation, the Michael Cuccione Foundation for Childhood Cancer Research, Cancer Research-UK (C490/A10119, C1287/A8874, C1287/A10118, C5047/A8385, and C8197/A10123), the National Institute for Health Research (UK), the Association for International Cancer Research (AICR-07-0454), the Ligue National Contre le Cancer (France), the Association ""Le cancer du sein, parlons-en!"", the Dutch Cancer Society (NKI 1998-1854, 2004-3088, and 2007-3756), the Fondazione Italiana per la Ricerca sul Cancro (""Hereditary Tumors""), the Associazione Italiana per la Ricerca sul Cancro (4017), the Italian Ministero della Salute (RFPS-2006-3-340203 and ""Progetto Tumori Femminili""), the Italian Ministero dell'Universita' e Ricerca (RBLAO3-BETH), the Fondazione IRCCS Istituto Nazionale Tumori (INT ""5x1000""), the Fondazione Cassa di Risparmio di Pisa (Istituto Toscano Tumori), the National Breast Cancer Foundation (Australia), the Australian National Health and Medical Research Council (145684, 288704, and 454508), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, the Cancer Foundation of Western Australia, the German Cancer Aid (107054), the Center for Molecular Medicine Cologne (TV93), the National Cancer Institute (USA; CA128978 and CA122340), National Institutes of Health (RFA-CA-06-503, BCFR U01 CA69398, CA69417, CA69446, CA69467, CA69631, and CA69638), the Research Triangle Institute Informatics Support Center (RFP N02PC45022-46), the Specialized Program of Research Excellence (SPORE P50 CA83638 and CA113916), the Department of Defense Breast Cancer Research Program (05/0612), the Eileen Stein Jacoby Fund, the @Disease$ Research Foundation, the Marianne and Robert MacDonald Foundation, the Komen Foundation, the Helsinki University Central Hospital Research Fund, the Academy of Finland (110663), the Finnish Cancer Society, the Sigrid Juselius Foundation, and the EU FP7 (223175, HEALTH-F2-2009-223175)"
493	@Gene$ staining of mouse mammary gland cells defines luminal epithelial, @Disease$/basal and non-epithelial cells.
494	Basal-like @Disease$ and the @Gene$ phenotype.
495	The basal phenotype of @Gene$-related @Disease$: past, present and future.
496	Aberrant luminal progenitors as the candidate target population for @Disease$ development in @Gene$ mutation carriers.
497	 @Gene$ basal-like @Disease$ originate from luminal epithelial progenitors and not from basal stem cells.
498	The pattern of expression of the microtubule-binding protein @Gene$/IHABP in mammary @Disease$ suggests a role in the invasive behaviour of tumour cells.
499	The pattern of expression of the microtubule-binding protein @Gene$/IHABP in mammary carcinoma suggests a role in the invasive behaviour of @Disease$ cells.
500	The pattern of expression of the microtubule-binding protein RHAMM/@Gene$ in mammary @Disease$ suggests a role in the invasive behaviour of tumour cells.
501	The pattern of expression of the microtubule-binding protein RHAMM/@Gene$ in mammary carcinoma suggests a role in the invasive behaviour of @Disease$ cells.
502	@Gene$ correlates with @Disease$ and maintains mitotic integrity.
503	A locus on 19p13 modifies risk of @Disease$ in @Gene$ mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.
504	A locus on 19p13 modifies risk of breast cancer in @Gene$ mutation carriers and is associated with hormone receptor-negative @Disease$ in the general population.
505	Common variants in @Gene$, 2q35 and 8q24 and @Disease$ risk for BRCA1 and BRCA2 mutation carriers.
506	Common variants in LSP1, 2q35 and 8q24 and @Disease$ risk for @Gene$ and BRCA2 mutation carriers.
507	Common variants in LSP1, 2q35 and 8q24 and @Disease$ risk for BRCA1 and @Gene$ mutation carriers.
508	Common @Disease$-predisposition alleles are associated with breast cancer risk in @Gene$ and BRCA2 mutation carriers.
509	Common @Disease$-predisposition alleles are associated with breast cancer risk in BRCA1 and @Gene$ mutation carriers.
510	Common breast cancer-predisposition alleles are associated with @Disease$ risk in @Gene$ and BRCA2 mutation carriers.
511	Common breast cancer-predisposition alleles are associated with @Disease$ risk in BRCA1 and @Gene$ mutation carriers.
512	 @Gene$ 135G C modifies @Disease$ risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.
513	 RAD51 135G C modifies @Disease$ risk among @Gene$ mutation carriers: results from a combined analysis of 19 studies.
514	@Gene$ expression and isoform balance predict @Disease$ and poor survival in multiple myeloma.
515	@Gene$ expression and isoform balance predict aggressive disease and poor survival in @Disease$.
516	@Gene$ and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated @Disease$.
517	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and @Gene$-associated @Disease$.
518	Identification of a new @Disease$/C recognition domain, the A box, which is required for the @Gene$-dependent destruction of the kinase Aurora-A during mitotic exit.
519	Identification of a new @Disease$/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase @Gene$ during mitotic exit.
520	@Gene$ kinase regulates @Disease$-associated gene 1 inhibition of centrosome-dependent microtubule nucleation.
521	 @Gene$ gene single nucleotide polymorphisms and risk of @Disease$.
522	Inconsistent association between the @Gene$ F31I genetic polymorphism and @Disease$ risk.
